We are live on ! Find out more

375 hedge funds and large institutions have $6.25B invested in ResMed in 2017 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 147 increasing their positions, 124 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more funds holding in top 10

Funds holding in top 10: 27 (+5)

60% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 35

19% more repeat investments, than reductions

Existing positions increased: 147 | Existing positions reduced: 124

14% more capital invested

Capital invested by funds: $5.47B → $6.25B (+$785M)

4% more funds holding

Funds holding: 362375 (+13)

1.14% less ownership

Funds ownership: 62.5%61.37% (-1.1%)

13% less call options, than puts

Call options by funds: $6.99M | Put options by funds: $8M

Holders
375
Holders Change
+13
Holders Change %
+3.59%
% of All Funds
9.3%
Holding in Top 10
7
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+250%
% of All Funds
0.17%
New
56
Increased
147
Reduced
124
Closed
35
Calls
$6.99M
Puts
$8M
Net Calls
-$1.02M
Net Calls Change
-$18.6M

RMD Hedge Fund Activity: Q1 2017 in Review

375 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q1 2017, worth a combined $6.25B — up 14% from $5.47B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new RMD positions and 35 closed out — a net gain of 21 holders — while 147 added to existing stakes and 124 trimmed.

The largest buyer was BlackRock, adding an estimated $905M. The largest seller was Panagora Asset Management, cutting an estimated $56.2M.

  • 375 institutional investors held ResMed (RMD) as of Q1 2017, up from 362 in Q4 2016.
  • Funds reported $6.25B of ResMed stock for Q1 2017, up 14% quarter-over-quarter.
  • 56 funds opened new ResMed positions in Q1 2017 and 35 closed out, a net change of +21 holders.
  • The largest ResMed buyer in Q1 2017 was BlackRock, an estimated $905M added.
  • The largest ResMed seller in Q1 2017 was Panagora Asset Management, an estimated $56.2M sold.

Based on aggregated 13F filings for Q1 2017.